Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXCELIS TECHNOLOGIES INCACLS · Entity 4152 | Director | February 17, 2021 | February 17, 2021 |
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | October 01, 2026 | October 03, 2026 |
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director · Chairman of the Board | October 01, 2026 | October 01, 2026 |
| Vyant Bio, Inc.VYNT · Entity 116415 | Director | January 17, 2023 | January 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXCELIS TECHNOLOGIES INC
Report date February 17, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,354 |
Reported balance
After 2021-02-17 transaction · row 1
1 source rowRow 1 · 2021-02-17 · Sale · Disposed 6,881 · Balance 1,354 |
ClearPoint Neuro, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,004 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 993 · Balance 132,004 F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
KORU Medical Systems, Inc.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 239,836 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 7,679 · Balance 239,836 |
Vyant Bio, Inc.
Report date January 17, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 23,895 |
Reported balance
After 2023-01-17 transaction · row 1
1 source rowRow 1 · 2023-01-17 · Grant · Acquired 4,368 · Balance 23,895 F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectBy R. John Fletcher 2015 Revocable Trust | 6,060 |
Reported balance
Holding disclosure · report date 2023-01-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,060 |
Filing footnotes · ownership attribution and instrument terms
F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,666 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.75 · Expires 2032-04-26 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 4,266 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
SPECTRANETICS CORP
Report date August 09, 2017 · Filed August 11, 2017
Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SPNC Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-09 transaction · row 1
1 source rowRow 1 · 2017-08-09 · Disposition to issuer · Disposed 141,697 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes.
F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 993 | $12.21 | $12,124.53 |
DisclosureSEC source: 0001193125-26-412424 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,004 F1 · price: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. Read SEC document |
| October 01, 2026 Filed Oct 1, 2026 21:23 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 7,679 | $2.93 | $22,499.47 |
DisclosureSEC source: 0001161697-26-000222 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,836 Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 21:18 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,357 | $4.20 | $22,499.40 |
DisclosureSEC source: 0001161697-26-000145 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,157 Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:05 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 662 | $17.84 | $11,810.08 |
DisclosureSEC source: 0001193125-26-296615 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,011 F1 · price: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2026. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-239427 · ownership.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,820 Underlying: Common Stock · 12,820 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2027 annual meeting of stockholders. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234574 · ownership.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,417 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 12,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-234574 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 20:48 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,208 | $4.32 | $22,498.56 |
DisclosureSEC source: 0001161697-26-000081 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,800 Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 18:53 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,270 | $9.10 | $11,557.00 |
DisclosureSEC source: 0001193125-26-139797 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,932 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2026. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 23:51 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,872 | $5.81 | $22,496.32 |
DisclosureSEC source: 0001161697-26-000010 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,592 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 23:40 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 422 | $13.68 | $5,772.96 |
DisclosureSEC source: 0001193125-26-002922 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,662 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2025. Read SEC document |
| October 02, 2025 Filed Oct 2, 2025 20:36 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,874 | $3.83 | $22,497.42 |
DisclosureSEC source: 0001161697-25-000334 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,720 Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 23:09 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 265 | $21.79 | $5,774.35 |
DisclosureSEC source: 0001193125-25-228835 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,240 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2025. Read SEC document |
| July 02, 2025 Filed Jul 2, 2025 20:50 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,284 | $3.58 | $22,496.72 |
DisclosureSEC source: 0001161697-25-000198 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,846 Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:45 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 484 | $11.94 | $5,778.96 |
DisclosureSEC source: 0000950170-25-093109 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,975 F1 · price: These shares were issued pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2025. Read SEC document |
| May 22, 2025 Filed May 23, 2025 22:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 12,417 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-077201 · ownership.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,417 Underlying: Common Stock · 12,417 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,266 | Not disclosed Strike: $33.75 | Not disclosed |
DisclosureSEC source: 0001104659-25-051348 · tm2515648-4_4seq1.xml · derivative · entry 3 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,266 shares Expires 2032-04-26 F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,566 | Not disclosed Strike: $17.70 | Not disclosed |
DisclosureSEC source: 0001104659-25-051348 · tm2515648-4_4seq1.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,566 shares Expires 2033-06-08 F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 21, 2025 Filed May 21, 2025 09:26 UTC | OptiNose, Inc. OPTN · Entity 79464 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,666 | Not disclosed Strike: $15.60 | Not disclosed |
DisclosureSEC source: 0001104659-25-051348 · tm2515648-4_4seq1.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,666 shares Expires 2034-06-06 F1 · kind: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2 · kind: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:01 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074519 · ownership.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:01 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 21,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074519 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 16, 2024, the reporting person was granted 21,093 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Read SEC document |
| April 02, 2025 Filed Apr 2, 2025 20:29 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 8,806 | $2.56 | $22,543.36 |
DisclosureSEC source: 0001161697-25-000132 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,562 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 00:23 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 486 | $11.89 | $5,778.54 |
DisclosureSEC source: 0000950170-25-049823 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,398 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2025. Read SEC document |
| January 03, 2025 Filed Jan 3, 2025 21:29 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,905 | $3.81 | $22,498.05 |
DisclosureSEC source: 0001161697-25-000019 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,756 Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:48 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 375 | $15.38 | $5,767.50 |
DisclosureSEC source: 0000950170-25-001298 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,912 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 31, 2024. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 20:04 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 8,181 | $2.75 | $22,497.75 |
DisclosureSEC source: 0001161697-24-000405 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,851 Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:22 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 515 | $11.21 | $5,773.15 |
DisclosureSEC source: 0001285550-24-000112 · wk-form4_1727900515.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,537 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2024. Read SEC document |
| July 11, 2024 Filed Jul 12, 2024 14:41 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 8,371 | $2.71 | $22,685.41 |
DisclosureSEC source: 0001161697-24-000307 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,670 Read SEC document |
| July 01, 2024 Filed Jul 2, 2024 21:20 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,072 | $5.39 | $5,778.08 |
DisclosureSEC source: 0001285550-24-000085 · wk-form4_1719955251.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,022 F1 · price: These shares were issued pursuant to the issuer's Fifth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 28, 2024. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 16:27 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001494650-24-000091 · wk-form4_1717792022.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:21 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 21,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000066 · wk-form4_1715977289.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,093 Underlying: Common Stock · 21,093 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:20 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-24-000058 · wk-form4_1715779234.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: On May 25, 2023, the reporting person was granted 17,153 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| May 14, 2024 Filed May 15, 2024 13:20 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | Exercise / conversionCommon Stock | 17,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001285550-24-000058 · wk-form4_1715779234.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| April 01, 2024 Filed Apr 2, 2024 20:44 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 850 | $6.80 | $5,780.00 |
DisclosureSEC source: 0001285550-24-000043 · wk-form4_1712090634.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,797 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 28, 2024. Read SEC document |
| March 31, 2024 Filed Apr 1, 2024 20:10 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 9,493 | $2.37 | $22,498.41 |
DisclosureSEC source: 0001161697-24-000168 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,353 Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:56 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 851 | $6.79 | $5,778.29 |
DisclosureSEC source: 0001285550-24-000004 · wk-form4_1704300979.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,947 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at December 29, 2023. Read SEC document |
| December 31, 2023 Filed Jan 2, 2024 21:48 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 9,493 | $2.37 | $22,498.41 |
DisclosureSEC source: 0001161697-24-000007 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,860 Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 16:41 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,153 | $5.01 | $5,776.53 |
DisclosureSEC source: 0001285550-23-000105 · wf-form4_169635127726527.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,096 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2023. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 20:16 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 8,226 | $2.74 | $22,539.24 |
DisclosureSEC source: 0001161697-23-000516 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,367 Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:46 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 798 | $7.24 | $5,777.52 |
DisclosureSEC source: 0001285550-23-000080 · wf-form4_168859358344306.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,943 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at June 30, 2023. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 20:12 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,465 | $3.48 | $22,498.20 |
DisclosureSEC source: 0001161697-23-000390 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,141 Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 14:06 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 53,500 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001494650-23-000059 · wk-form4_1686333996.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,500 Underlying: Common Stock · 53,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 8, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 25, 2023 Filed May 26, 2023 18:10 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantRestricted Stock Units · Derivative | 17,153 | $0.00 | $0.00 |
DisclosureSEC source: 0001285550-23-000061 · wf-form4_168512464277542.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,153 Underlying: Common Stock · 17,153 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2024 annual meeting of stockholders. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:57 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 684 | $8.44 | $5,772.96 |
DisclosureSEC source: 0001285550-23-000038 · wf-form4_168064182283698.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,145 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at March 31, 2023. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 20:04 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,281 | $4.26 | $22,497.06 |
DisclosureSEC source: 0001161697-23-000213 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,380 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 20:06 UTC Amendment | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 5,281 | $4.26 | $22,497.06 |
DisclosureSEC source: 0001161697-23-000233 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,676 Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:30 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 4,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-001919 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,895 F1 · shares: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date. F1 · price: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 22:58 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,175 | $7.97 | $17,334.75 |
DisclosureSEC source: 0001285550-23-000006 · wf-form4_167287309071574.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,461 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $7.97 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending December 30, 2022. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 21:46 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 6,410 | $3.51 | $22,499.10 |
DisclosureSEC source: 0001161697-23-000023 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,395 Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 13:00 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 8,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-028715 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,649 F1 · shares: On October 17, 2022, the Reporting Person was granted 8,290 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on October 17, 2023, so long as Reporting Person remains a director though that date. F1 · price: On October 17, 2022, the Reporting Person was granted 8,290 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on October 17, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.